Inactive

TITLE The procurement of a Illumina NextSeq2000. BRAND NAME OR EQUAL This requirement is for the procurement of the brand name or equivalent instrument described in section 4.0. The Federal Acquisitio... TITLE The procurement of a Illumina NextSeq2000. BRAND NAME OR EQUAL This requirement is for the procurement of the brand name or equivalent instrument described in section 4.0. The Federal Acquisition Regulation (FAR) provision FAR 52.211-6, Brand Name or Equal (AUG 1999) is applicable to this requirement. BACKGROUND The purpose of this acquisition is to trade-in an existing NextSeq550 (S/N NB1349) to procure the illumina NextSeq™ 2000. The NextSeq2000 represents the newest generation of multiplexed, high throughput sequencing systems with fast, accurate results, and is the only personal sequencing platform on the market designed with extensibility from 20 Gb to 300 Gb with flexible informatics options. Over the last 20 years, Illumina has led the charge to improve sequencing capabilities across the entire workflow, making it easier to use while driving down costs. With a choice of cell formats, multiple read length configurations, the NextSeq2000 will enable data output ranging from ~20 Gb-300 Gb per run, providing flexibility across a broad range of applications and study sizes at a lower cost to our NCI investigators. The NextSeq 2000 Sequencing System features a novel super resolution optics system and the next iteration of industry leading sequencing by synthesis (SBS) chemistry that yields highly accurate imaging data with greater resolution and higher sensitivity and optimized to increase cluster brightness, reduce channel cross-talk, and improve signal-to-noise ratio than traditional benchtop systems. The on-board DRAGEN platform uses optimized, hardware-accelerated algorithms for a wide variety of genomic analysis solutions, including BCL conversion, mapping, alignment, sorting, duplicate marking, and variant calling. The Illumina Nextseq 2000 is the only instrument that meets all of these requirements. This instrument is available only from its manufacturer, Illumina Inc. TYPE OF ORDER This is a Firm Fixed-Price Purchase Order. SPECIAL ORDER REQUIREMENTS PRODUCT FEATURES/SALIENT CHARACTERISTICS The following product features/characteristics are required for this requirement: Sequencing chemistries must be compatable with iSeq Sequencing system and other government-owned illumina sequencing systems Output requirements ranging from ~20 Gb-300 Gb per run Sequencing run time between 11-48 hours Number of samples per run up to 22 On-board DRAGEN platform for secondary analysis DELIVERY / INSTALLATION Contractor shall deliver the systems within 4-12 weeks after award to: CCR Genomics Core National Cancer Institute 37 Convent Drive MSC 4256 Bethesda, MD 20892-4256 TRAINING Contractor shall provide training on proper use of equipment, software and related use NCI researchers at above location within one week of installation, and the training will be provided by the premium support scientist, or other illumina personnel, on an as needed basis. WARRANTY The Contractor shall warrant that any instruments, equipment, components, or other supplies (“Supplies”) procured by this purchase are free of defects in design, material, or manufacture for a period of at least one (1) calendar year from date of acceptance by the Government. The Contractor shall warrant that all consumables or expendable parts are free of defects in design, material or manufacture for a period of at least 90 calendar days from date of acceptance by the Government. Supplies which are repaired or replaced shall be warranted for the remainder of the initial warranty period or for 90-days – whichever is greater.